IP Library Granted Patent US 9,540,660
Granted Patent B2
US 9,540,660 · App. 14/641,669 · Granted Jan 10, 2017

Vector comprising multiple homologous nucleotide sequences

Inventor: Robin Steigerwald (Munich, DE)
Assignee: BAVARIAN NORDIC A/S
C12N15/86C12N2710/24134C12N2710/24143C12N2710/24151C12N2740/11022C12N2760/14122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,660
App. No.
14/641,669
Granted
Jan 10, 2017
Kind
B2
Abstract

The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.

Claims (27)

1. A method for generating a stable modified vaccinia Ankara (MVA) virus vector comprising:

providing a vector or vectors containing two nucleotide sequences of at least 2000 nucleotides each, wherein each nucleotide sequence encodes a single Ebola virus glycoprotein;

substituting at least 400 nucleotides in one or both of the nucleotide sequence(s) to generate two divergent sequences;

wherein the 400 substituted nucleotides do not alter the amino acids encoded by the two divergent sequences; and

generating a stable MVA vector comprising the two divergent sequences stably inserted into the MVA genome,

wherein the two divergent sequences share stretches of identity of no more than 10 contiguous nucleotides; and

wherein the two nucleotide sequences encode Ebola virus Sudan and Ebola virus Zaire glycoproteins.

2. The method of claim 1 , wherein the substitutions increase the overall nucleotide identity between the two nucleotide sequences.

3. The method of claim 1 , wherein the two divergent sequences comprise the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:13.

4. A method for generating a stable modified vaccinia Ankara (MVA) virus vector comprising:

providing two nucleotide sequences of at least 2000 nucleotides each, wherein each nucleotide sequence encodes a single Ebola virus glycoprotein;

substituting at least 400 nucleotides in one or both of the nucleotide sequence(s) to generate two divergent sequences;

wherein the 400 substituted nucleotides do not after the amino acids encoded by the two divergent sequences; and

generating a stable MVA vector comprising the two divergent sequences stably inserted into the MVA genome,

wherein the two divergent sequences share stretches of identity of no more than 10 contiguous nucleotides; and

wherein the two nucleotide sequences encode Ebola virus Sudan and Ebola virus Zaire glycoproteins.

5. The method of claim 4 , wherein the substitutions increase the overall nucleotide identity between the two nucleotide sequences.

6. The method of claim 4 , wherein the two divergent sequences comprise the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:13.

7. A method for generating a stable modified vaccinia Ankara (MVA) virus vector comprising:

providing first and second nucleotide sequences of at least 2000 nucleotides each,

wherein each nucleotide sequence encodes a single Ebola virus glycoprotein,

wherein one of the two nucleotide sequences is a substituted nucleotide sequence, having at least 400 substituted nucleotides different from the other nucleotide sequence,

wherein the substituted nucleotides do not alter the amino acids encoded by the first and second nucleotide sequences,

and wherein the two nucleotide sequences share stretches of identity of no more than 10 contiguous nucleotides; and

inserting the first and second nucleotide sequences into an MVA vector to generate a stable MVA vector,

wherein the two nucleotide sequences encode Ebola virus Sudan and Ebola virus Zaire glycoproteins.

8. The method of claim 7 , wherein the first and second nucleotide sequences comprise the sequences of SEQ ID NO:12 and SEQ ID NO:13.

Continuity (3)
Continuation 13123605
Provisional Application 61116672 · Nov 21, 2008
Related Publication 20160017369A1 · Jan 21, 2016